FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2003200123> ?p ?o ?g. }

• W2003200123 endingPage "644" @default.
• W2003200123 startingPage "639" @default.
• W2003200123 abstract "A chimerized (murine/human) monoclonal antibody (pagibaximab) against lipoteichoic acid (LTA) and protective in animal models for coagulase-negative staphylococci (CONS) and Staphylococcus aureus bacteremia, was developed for prevention of staphylococcal infection in high-risk populations. This open label two-dose study of a single intravenous dose of 3 or 10 mg/kg of pagibaximab evaluated the safety/tolerability, pharmacokinetics, and opsonophagocytic activity of pagibaximab in healthy adults. Eight participants were enrolled (four in each dose group). No infusion, drug, or dose related adverse events occurred. Serum anti-LTA levels were dose-related; mean concentrations peaked at 87.75 and 259.24 μg/mL for 3 and 10 mg/kg groups, respectively. The half-life (beta) of pagibaximab was approximately 33 days. Opsonophagocytic activity of serum samples on a human clinical isolate of Staphylococcus epidermidis in a standard bacterial killing assay was dose-related, and peaked at a mean of 88.5 and 95.5% at 1:90 dilution for 3 and 10 mg/kg groups, respectively. Serum anti-LTA and opsonophagocytic activity levels exhibited statistically significant correlation. The results suggest that pagibaximab at 3 and 10 mg/kg administered as a single intravenous dose in healthy adults appears to: 1) provide preliminary safety and tolerability data, 2) produce dose-related serum anti-LTA and opsonophagocytic activity levels, 3) have a half-life similar to other immunoglobulin G1 antibodies, 4) exhibit statistically significant correlation between serum anti-LTA and opsonophagocytic activity levels. This study supports conducting safety and pharmacokinetic trials of pagibaximab in populations at high-risk of developing CONS infection." @default.
• W2003200123 created "2016-06-24" @default.
• W2003200123 creator A5010740129 @default.
• W2003200123 creator A5012193675 @default.
• W2003200123 creator A5021978799 @default.
• W2003200123 creator A5034709604 @default.
• W2003200123 creator A5044855145 @default.
• W2003200123 creator A5058606727 @default.
• W2003200123 creator A5067657695 @default.
• W2003200123 creator A5071974491 @default.
• W2003200123 creator A5075818401 @default.
• W2003200123 creator A5079233882 @default.
• W2003200123 date "2009-05-01" @default.
• W2003200123 modified "2023-09-26" @default.
• W2003200123 title "Safety and pharmacokinetics of a chimerized anti-lipoteichoic acid monoclonal antibody in healthy adults" @default.
• W2003200123 cites W184447267 @default.
• W2003200123 cites W1955146178 @default.
• W2003200123 cites W1985494046 @default.
• W2003200123 cites W2015488597 @default.
• W2003200123 cites W2026746053 @default.
• W2003200123 cites W2039093895 @default.
• W2003200123 cites W2040505385 @default.
• W2003200123 cites W2057486405 @default.
• W2003200123 cites W2075917748 @default.
• W2003200123 cites W2119910833 @default.
• W2003200123 cites W2140076442 @default.
• W2003200123 cites W2164493556 @default.
• W2003200123 cites W2329427515 @default.
• W2003200123 cites W2335360346 @default.
• W2003200123 doi "https://doi.org/10.1016/j.intimp.2009.02.008" @default.
• W2003200123 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19268719" @default.
• W2003200123 hasPublicationYear "2009" @default.
• W2003200123 type Work @default.
• W2003200123 sameAs 2003200123 @default.
• W2003200123 citedByCount "34" @default.
• W2003200123 countsByYear W20032001232012 @default.
• W2003200123 countsByYear W20032001232013 @default.
• W2003200123 countsByYear W20032001232014 @default.
• W2003200123 countsByYear W20032001232015 @default.
• W2003200123 countsByYear W20032001232016 @default.
• W2003200123 countsByYear W20032001232018 @default.
• W2003200123 countsByYear W20032001232019 @default.
• W2003200123 countsByYear W20032001232020 @default.
• W2003200123 countsByYear W20032001232021 @default.
• W2003200123 countsByYear W20032001232022 @default.
• W2003200123 countsByYear W20032001232023 @default.
• W2003200123 crossrefType "journal-article" @default.
• W2003200123 hasAuthorship W2003200123A5010740129 @default.
• W2003200123 hasAuthorship W2003200123A5012193675 @default.
• W2003200123 hasAuthorship W2003200123A5021978799 @default.
• W2003200123 hasAuthorship W2003200123A5034709604 @default.
• W2003200123 hasAuthorship W2003200123A5044855145 @default.
• W2003200123 hasAuthorship W2003200123A5058606727 @default.
• W2003200123 hasAuthorship W2003200123A5067657695 @default.
• W2003200123 hasAuthorship W2003200123A5071974491 @default.
• W2003200123 hasAuthorship W2003200123A5075818401 @default.
• W2003200123 hasAuthorship W2003200123A5079233882 @default.
• W2003200123 hasConcept C112705442 @default.
• W2003200123 hasConcept C159654299 @default.
• W2003200123 hasConcept C197934379 @default.
• W2003200123 hasConcept C203014093 @default.
• W2003200123 hasConcept C2778375690 @default.
• W2003200123 hasConcept C2779489039 @default.
• W2003200123 hasConcept C523546767 @default.
• W2003200123 hasConcept C54355233 @default.
• W2003200123 hasConcept C6977687 @default.
• W2003200123 hasConcept C71924100 @default.
• W2003200123 hasConcept C86803240 @default.
• W2003200123 hasConcept C89423630 @default.
• W2003200123 hasConcept C98274493 @default.
• W2003200123 hasConceptScore W2003200123C112705442 @default.
• W2003200123 hasConceptScore W2003200123C159654299 @default.
• W2003200123 hasConceptScore W2003200123C197934379 @default.
• W2003200123 hasConceptScore W2003200123C203014093 @default.
• W2003200123 hasConceptScore W2003200123C2778375690 @default.
• W2003200123 hasConceptScore W2003200123C2779489039 @default.
• W2003200123 hasConceptScore W2003200123C523546767 @default.
• W2003200123 hasConceptScore W2003200123C54355233 @default.
• W2003200123 hasConceptScore W2003200123C6977687 @default.
• W2003200123 hasConceptScore W2003200123C71924100 @default.
• W2003200123 hasConceptScore W2003200123C86803240 @default.
• W2003200123 hasConceptScore W2003200123C89423630 @default.
• W2003200123 hasConceptScore W2003200123C98274493 @default.
• W2003200123 hasIssue "5" @default.
• W2003200123 hasLocation W20032001231 @default.
• W2003200123 hasLocation W20032001232 @default.
• W2003200123 hasOpenAccess W2003200123 @default.
• W2003200123 hasPrimaryLocation W20032001231 @default.
• W2003200123 hasRelatedWork W1991039113 @default.
• W2003200123 hasRelatedWork W2037576960 @default.
• W2003200123 hasRelatedWork W2064482552 @default.
• W2003200123 hasRelatedWork W2074207917 @default.
• W2003200123 hasRelatedWork W2396178441 @default.
• W2003200123 hasRelatedWork W2789968340 @default.
• W2003200123 hasRelatedWork W4205587618 @default.
• W2003200123 hasRelatedWork W4253098345 @default.
• W2003200123 hasRelatedWork W4296087748 @default.
• W2003200123 hasRelatedWork W4366822339 @default.

• next